for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mithra Pharmaceuticals SA

MITRA.BR

Latest Trade

26.20EUR

Change

-0.98(-3.61%)

Volume

53,657

Today's Range

26.04

 - 

27.18

52 Week Range

18.12

 - 

32.96

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
27.18
Open
27.18
Volume
53,657
3M AVG Volume
1.34
Today's High
27.18
Today's Low
26.04
52 Week High
32.96
52 Week Low
18.12
Shares Out (MIL)
37.69
Market Cap (MIL)
987.45
Forward P/E
61.89
Dividend (Yield %)
--

Next Event

Mithra Pharmaceuticals SA Annual Shareholders Meeting

Latest Developments

More

Mithra Signs Agreement For Commercialization Of Myring™ In China With Abbott

Mithra Pharmaceuticals Initiates Phase III Clinical Program For Donesta

Mithra Provides Supplementary Details On Estelle® Us Deal With Mayne

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.

Industry

Biotechnology & Drugs

Contact Info

Rue Saint-Georges 5

+32.4.3492822

https://www.mithra.com/

Executive Leadership

Marc Coucke

Non-Executive Chairman of the Board Representing Alychlo NV

Francois Fornieri

Chief Executive Officer, Chief Business Development Officer, Executive Director - Representative of YIMA SPRL

Christophe Marechal

Chief Financial Officer - Representing CMM&C SPRL

Patrick Kellens

Chief Information Officer

Graham K. Dixon

Chief Scientific Officer

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

-1.130

2017

-1.370

2018

-0.340

2019(E)

0.423
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.96
Price To Book (MRQ)
15.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
420.38
LT Debt To Equity (MRQ)
393.80
Return on Investment (TTM)
-28.45
Return on Equity (TTM)
-25.64

Latest News

Latest News

BRIEF-Mithra Pharmaceuticals Potential New Perimenopause Product Launch In 2023

* MITHRA ANNOUNCED ON MONDAY POTENTIAL FOR NEW PERIMENOPAUSE PRODUCT CANDIDATE PERINESTA LAUNCH AS EARLY AS 2023

BRIEF- Mithra Pharmaceuticals Provides Update On Its Key Programmes

* US/CANADA PHASE III ARM OF ESTELLE® ORAL CONTRACEPTION DUE TO COMPLETE IN Q4 2018

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma

* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA

BRIEF-Mithra Pharmaceuticals Applies For Additional Estelle® Patent Based On Positive Hemostasis Data

* MITHRA APPLIES FOR ADDITIONAL ESTELLE® PATENT BASED ON POSITIVE HEMOSTASIS DATA

BRIEF-Mithra Pharmaceuticals And Mayne Pharma's Vaginal Contraceptive Ring Accepted For Filing By FDA​

* MITHRA AND MAYNE PHARMA'S VAGINAL CONTRACEPTIVE RING ACCEPTED FOR FILING BY FDA

BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle

* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLE®,

BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​

* MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®

BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​

* MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY

BRIEF-Mithra Pharmaceuticals And Adamed Sign Commercialization Agreement For Myring™ In The Czech Republic

* MITHRA AND ADAMED SIGN COMMERCIALIZATION AGREEMENT FOR MYRING™ IN THE CZECH REPUBLIC

BRIEF-Mithra Pharmaceuticals Announces Injectables Agreement With GSP

* MITHRA CLOSES CONTRACTS WITH LEADING GENERICS PLAYER GSP FOR DEVELOPMENT AND SUPPLY OF 4 HORMONAL INJECTABLES

BRIEF-Mithra Pharmaceuticals Finalizes Estelle Contract With Libbs

* FINALIZES ESTELLE CONTRACT WITH BRAZILIAN WOMEN’S HEALTH LEADER LIBBS

BRIEF-Mithra Announces Valorization Of French Subsidiary

* SUCCESSFULLY DIVESTED ITS FRENCH AFFILIATE, MITHRA FRANCE

BRIEF-Mithra Pharmaceuticals Announces Update On Clinical Study Progress For Estelle And Donesta

* ANNOUNCES AN UPDATE ON THE CLINICAL STUDY PROGRESS FOR ESTELLE AND DONESTA

BRIEF-Mithra Pharmaceuticals announces 36-month shelf life extension for Tibelia​

* MITHRA ANNOUNCES 36-MONTH SHELF LIFE EXTENSION FOR TIBELIA

BRIEF-Mithra Pharmaceuticals ‍completes recruitment for Estelle Phase III study in US and Canada​

* COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US AND CANADA

BRIEF-Mithra Pharmaceuticals' application for Tibelia marketing authorization accepted by Health Canada

* MITHRA’S MARKETING AUTHORIZATION APPLICATION FOR TIBELIA ACCEPTED BY HEALTH CANADA

BRIEF-Mithra Pharmaceuticals signs commercial agreement with Libbs

* MITHRA PHARMACEUTICALS SA - MITHRA SIGNS COMMERCIAL AGREEMENT WITH BRAZILIAN LEADER IN WOMEN’S HEALTH LIBBS FOR ESTELLE® IN BRAZIL

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up